Selective Inhibition of P2Y and P2Y Receptor Signal Pathways in Platelet Aggregation in Transgenic Cell Lines and Rats by Potassium 2-(1-Hydroxypentyl)-Benzoate, Puerarin and Salvianolic Acid B

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2024 Nov 20

PMID 39563013

Authors

Yiying Li

Weiping Wang

Jie Cai

Nan Feng

Shaofeng Xu

Ling Wang

Xiaoliang Wang

Affiliations

Soon will be listed here.

Abstract

Aim: Potassium 2-(1-hydroxypentyl)-benzoate (dl-PHPB), puerarin and salvianolic acid B are three natural products or derivatives that can inhibit platelet aggregation. However, the mechanisms of dl-PHPB, puerarin and salvianolic acid B to inhibit platelet aggregation are still not clear.

Method: Here, 2-methylthioadenosine diphosphate (2-MeSADP) was used as an inducer to confirm the effects of three drugs on platelet aggregation and illustrate the corresponding mechanisms.

Result: The results indicated that dl-PHPB, puerarin and salvianolic acid B significantly inhibited platelet aggregation both in vivo and in vitro. In addition, the content of IP, cAMP and intracellular [Ca] were measured in HEK293 cell lines overexpressing P2Y and P2Y. Dl-PHPB and puerarin could obviously reduce 2-MeSADP-induced IP increase, but salvianolic acid B showed no effects. Unlike dl-PHPB and puerarin, which had no effects on 2-MeSADP-induced cAMP decrease, salvianolic acid B significantly reversed the reduction of cAMP. Both dl-PHPB and puerarin could decrease the enhanced intracellular [Ca] induced by 2-MeSADP; however, salvianolic acid B showed no effect on intracellular [Ca] elevation.

Conclusion: These results suggested that dl-PHPB and puerarin inhibited platelet aggregation via targeting at P2Y receptor and P2Y-Gq-IP-Ca signal pathway. Differently, salvianolic acid B inhibited platelet aggregation via targeting at P2Y receptor and via Gi-AC-cAMP signal pathway.

References

Qi R, Liao F, Inoue K, Yatomi Y, Sato K, Ozaki Y . Inhibition by diallyl trisulfide, a garlic component, of intracellular Ca(2+) mobilization without affecting inositol-1,4, 5-trisphosphate (IP(3)) formation in activated platelets. Biochem Pharmacol. 2000; 60(10):1475-83. DOI: 10.1016/s0006-2952(00)00467-6. View

. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996; 348(9038):1329-39. DOI: 10.1016/s0140-6736(96)09457-3. View

Li S, Feng X, Xu H, Chen K . Comparison on Anticoagulation and Antiplatelet Aggregation Effects of Puerarin with Heparin Sodium and Tirofiban Hydrochloride: An In Vitro Study. Chin J Integr Med. 2017; 24(2):103-108. DOI: 10.1007/s11655-017-2419-7. View

. Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994; 308(6921):81-106. PMC: 2539220. View

Guan B, Gao J, Tan Y, Ma X, Shi D . Antiplatelet Activity of Tetramethylpyrazine via Regulation of the P2Y12 Receptor Downstream Signaling Pathway. Evid Based Complement Alternat Med. 2022; 2022:7941039. PMC: 8976642. DOI: 10.1155/2022/7941039. View

Jacobson K, Gao Z . Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):247-64. PMC: 3463109. DOI: 10.1038/nrd1983. View

Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P . Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J Clin Invest. 1999; 104(12):1731-7. PMC: 409888. DOI: 10.1172/JCI8399. View

Liu R, Xing D, Lu H, Wu H, Du L . Pharmacokinetics of puerarin and ginsenoside Rg1 of CBN injection and the relation with platelet aggregation in rats. Am J Chin Med. 2006; 34(6):1037-45. DOI: 10.1142/S0192415X06004508. View

Liu L, Li J, Zhang Y, Zhang S, Ye J, Wen Z . Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory. Thromb Res. 2014; 134(4):866-76. DOI: 10.1016/j.thromres.2014.07.019. View

10.

Jagroop I, Burnstock G, Mikhailidis D . Both the ADP receptors P2Y1 and P2Y12, play a role in controlling shape change in human platelets. Platelets. 2003; 14(1):15-20. DOI: 10.1080/0953710021000062914. View

11.

Wu C, Tsai F, Chen M, Wu S, Lee M, Tsai T . Antipsychotic Drugs Inhibit Platelet Aggregation via P2Y 1 and P2Y 12 Receptors. Biomed Res Int. 2016; 2016:2532371. PMC: 4812202. DOI: 10.1155/2016/2532371. View

12.

Lei Y, Zhang B, Liu D, Zhao J, Dai X, Gao J . Switching a Xanthine Oxidase Inhibitor to a Dual-Target Antagonist of P2Y and P2Y as an Oral Antiplatelet Agent with a Wider Therapeutic Window in Rats than Ticagrelor. J Med Chem. 2020; 63(24):15752-15772. DOI: 10.1021/acs.jmedchem.0c01524. View

13.

Leon C, Vial C, Cazenave J, Gachet C . Cloning and sequencing of a human cDNA encoding endothelial P2Y1 purinoceptor. Gene. 1996; 171(2):295-7. DOI: 10.1016/0378-1119(96)00027-3. View

14.

Hongyun H, Tao G, Pengyue Z, Liqiang Y, Yihao D . Puerarin provides a neuroprotection against transient cerebral ischemia by attenuating autophagy at the ischemic penumbra in neurons but not in astrocytes. Neurosci Lett. 2017; 643:45-51. DOI: 10.1016/j.neulet.2017.02.009. View

15.

Leon C, Hechler B, Vial C, Leray C, Cazenave J, Gachet C . The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett. 1997; 403(1):26-30. DOI: 10.1016/s0014-5793(97)00022-7. View

16.

Li X, Tang H, Zhang L, Yang L, Li P, Chen J . A selective knockout method for discovery of minor active components from plant extracts: Feasibility and challenges as illustrated by an application to Salvia miltiorrhiza. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1068-1069:253-260. DOI: 10.1016/j.jchromb.2017.10.011. View

17.

Chen Z, Sandercock P, Pan H, Counsell C, Collins R, Liu L . Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke. 2000; 31(6):1240-9. DOI: 10.1161/01.str.31.6.1240. View

18.

Zeller J, Tschoepe D, Kessler C . Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemost. 1999; 81(3):373-7. View

19.

Chen B, Dang L, Zhang X, Fang W, Hou M, Liu T . Physicochemical properties and micro-structural characteristics in starch from kudzu root as affected by cross-linking. Food Chem. 2016; 219:93-101. DOI: 10.1016/j.foodchem.2016.09.128. View

20.

van Kooten F, Ciabattoni G, Koudstaal P, Dippel D, Patrono C . Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. Stroke. 1999; 30(3):546-9. DOI: 10.1161/01.str.30.3.546. View